Bristol Myers Squibb (BMS) announced H1 2025 revenue of USD 23.5 billion, down 2% year-on-year, with growth products like Opdivo (nivolumab) and Breyanzi (lisocabtagene maraleucel) offsetting declines in mature brands. Opdivo sales rose 8% to USD 4.8 billion, driven by its use in combination therapies, while CD19 CAR-T therapy Breyanzi surged 134% to USD 607 million, capturing the US market lead in Q2. The company also highlighted progress in cardiovascular drugs, with Camzyos (mavacamten) for hypertrophic cardiomyopathy growing 88% to USD 419 million.

BMS strengthened its oncology pipeline through collaborations, including a deal with BioNTech for PD-L1/VEGF bispecific antibody (BsAb) BNT327. The company raised its full-year revenue guidance to USD 46.5 to 47.5 billion, reflecting confidence in growth products like erythroid maturation agent Reblozyl (luspatercept), which grew 34% to USD 1 billion. Key upcoming milestones include Phase III readouts for Alzheimer's disease psychosis (ADP) drug Cobenfy (xanomeline+trospium) and subcutaneous Opdivo formulations.

PharmCube's NextBiopharm® database shows that Breyanzi has seen its sales double every year since its 2021 launch, almost reaching 2024's full-year revenue during H1 2025. Click here to request a free trial for NextBiopharm®.